Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Morphic closes $80mm Series B

Executive Summary

Morphic Therapeutic Inc. (working on oral integrin therapies for autoimmune diseases, fibrotic diseases, and cancer) raised $80mm in its Series B financing led by Omega Funds and Novo Holdings, which each add a board member. New backers Invus and EcoR1 Capital were joined by Series A investors SR One, Pfizer Venture Investments, AbbVie Ventures, Polaris Partners, TA Springer (a board member), Schrodinger, and ShangPharma Investment Group. Morphic will use the proceeds to bring its two lead candidates through clinical proof-of-concept and to move other programs into human studies.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies